Pharmacy Compounding: FDA alerts health care professionals of adverse events associated with Guardian’s compounded triamicinolone and moxifloxacin product for intravitreal injection

FDA alerts health care professionals of adverse events associated with Guardian’s compounded triamicinolone and moxifloxacin product for intravitreal injection

[07/28/2017] The U.S. Food and Drug Administration received adverse event reports on April 5 and June 1, 2017, and conducted follow-up, concerning at least 43 patients who were administered intravitreal (eye) injections of a drug containing triamcinolone (steroid) and moxifloxacin (anti-infective) compounded by Guardian Pharmacy Services in Dallas, Texas. The patients were administered Guardian’s product at the end of a cataract surgery procedure at the PRG Dallas Ambulatory Surgery Center in Dallas, Texas, by physicians affiliated with the Key Whitman Eye Center, and at the Park Central Surgical Center in Dallas, Texas, by physicians affiliated with Tylock-George Eye Care. Read more on our website